http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2870717-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0acc7fd312a68983fb8b9d120043467e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2013-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e277188c866af5439694ba801a8cca75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_849920c1ae08fd4df9f83a4061d5c1de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c2e68db7b78fbac7f576af9dc037f8f |
| publicationDate | 2021-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2870717-T3 |
| titleOfInvention | Human antibodies and specific binding sequences thereof for use in stroke and ischemia and ischemic conditions |
| abstract | An isolated human IgM antibody or fragment thereof that specifically binds to neurons and protects neurons from cell death and does not promote remyelination, wherein the isolated human IgM antibody or fragment comprises the following sequence: (a ) the heavy chain variable amino acid CDR domain sequences CDR1 GGSVSLYY (SEQ ID NO: 31), CDR2 GYIYSSGST (SEQ ID NO: 32), and CDR3 ARSASIRGWFD (SEQ ID NO: 33), and the CDR sequences of CDR1 QSISSY light chain (SEQ ID NO: 34), CDR2 AAS (SEQ ID NO: 35) and CDR3 QQSYHTPW (SEQ ID NO: 36), as set forth in Figure 5; or (b) the heavy chain variable amino acid CDR domain sequences CDR1 GFTFSTYA (SEQ ID NO: 37), CDR2 INVGGVTT (SEQ ID NO: 38), and CDR3 VRRSGPDRNSSPADF (SEQ ID NO: 39), and the sequences of Light chain CDRs CDR1 QGIG (SEQ ID NO: 40), CDR2 TTS (SEQ ID NO: 41), and CDR3 QKYNSAPRT (SEQ ID NO: 42), as set forth in Figure 6, for use in a method for treating or to improve cerebral ischemia or stroke, to improve neural function in an animal after a stroke or cerebral ischemia, or to protect neurons or neural cells from damage or cell death after a stroke or cerebral ischemia, wherein the method comprises administering the isolated human IgM antibody or fragment thereof in combination with a remyelinating antibody, and wherein the remyelinating antibody comprises: (i) heavy chain variable region CDRs comprising the CDR1 SSGMH sequence (SEQ ID NO: 47), the sequence of CDR2 V(I)ISYDGSRKYYADSVKG (SEQ ID NO: 48) and the CDR3 sequence GVTGSPTLDY (SEQ ID NO: 49), and light chain variable region CDRs comprising the CDR1 sequence SGSSSNIGNNFVS (SEQ ID NO: 50), the CDR2 sequence DITKRPS (SEQ ID NO: 51) and the CDR3 sequence G(E)TWDSSLSAW (SEQ ID NO: 52); or (ii) the heavy chain variable region CDRs comprising the CDR1 sequence SGFTFSSYW (SEQ ID NO: 53), the CDR2 sequence IKKDGSEK (SEQ ID NO: 54), and the CDR3 sequence ARPNCGGDCYLPWYFD (SEQ ID NO: 55), and light chain variable region CDRs comprising the CDR1 sequence QSVLYSSNNKNY (SEQ ID NO: 56), the CDR2 sequence YWAS (SEQ ID NO: 57), and the CDR3 sequence QQYYNTPQA (SEQ ID NOT: 58). |
| priorityDate | 2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 782.